Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00754988




Registration number
NCT00754988
Ethics application status
Date submitted
17/09/2008
Date registered
18/09/2008
Date last updated
4/11/2016

Titles & IDs
Public title
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Scientific title
A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.
Secondary ID [1] 0 0
2008-001854-42
Secondary ID [2] 0 0
BC21713
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Metformin
Treatment: Drugs - Placebo (matching sitagliptin)
Treatment: Drugs - Placebo (matching taspoglutide)
Treatment: Drugs - Sitagliptin
Treatment: Drugs - Taspoglutide

Placebo Comparator: Placebo - Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.

Active Comparator: Sitagliptin - Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.

Experimental: Taspoglutide 10 mg - Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.

Experimental: Taspoglutide up-titrated to 20 mg - Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.


Treatment: Drugs: Metformin
As prescribed

Treatment: Drugs: Placebo (matching sitagliptin)
Once daily oral administration of placebo (matching sitagliptin).

Treatment: Drugs: Placebo (matching taspoglutide)
Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).

Treatment: Drugs: Sitagliptin
Once daily oral administration of 100 mg of sitagliptin.

Treatment: Drugs: Taspoglutide
Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean changes in HbA1c
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Change from baseline in fasting plasma glucose; change from baseline in body weight; responder rates for HbA1c (target <=7.0%, <=6.5%); responder rates for body weight; change from baseline in lipid profile; beta cell function.
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.
Timepoint [2] 0 0
Throughout study

Eligibility
Key inclusion criteria
- adult patients, 18-75 years of age;

- type 2 diabetes receiving metformin (>=1500mg/day) for at least 12 weeks;

- HbA1c >=7.0% and <=10.0% at screening;

- BMI >=25 (>23 for Asians) and <=45kg/m2 at screening;

- stable weight +/- 5% for at least 12 weeks prior to screening.
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- history of type 1 diabetes mellitus or acute metabolic diabetic complications such as
ketoacidosis or hyperosmolar coma in the previous 6 months;

- evidence of clinically significant diabetic complications;

- clinically symptomatic gastrointestinal disease;

- myocardial infarction, coronary artery bypass surgery, post-transplantation
cardiomyopathy or stroke within the previous 6 months;

- known hemoglobinopathy or chronic anemia.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2011
Sample size
Target
Accrual to date
Final
666
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
- Freemantle
Recruitment hospital [2] 0 0
- Adelaide
Recruitment postcode(s) [1] 0 0
6959 - Freemantle
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Hawaii
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Vermont
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Mar del Plata
Country [30] 0 0
Canada
State/province [30] 0 0
Ontario
Country [31] 0 0
Canada
State/province [31] 0 0
Quebec
Country [32] 0 0
France
State/province [32] 0 0
Bondy
Country [33] 0 0
France
State/province [33] 0 0
Nantes
Country [34] 0 0
France
State/province [34] 0 0
Poitiers
Country [35] 0 0
France
State/province [35] 0 0
Rennes
Country [36] 0 0
France
State/province [36] 0 0
St Mande
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Dormagen
Country [39] 0 0
Germany
State/province [39] 0 0
Dresden
Country [40] 0 0
Germany
State/province [40] 0 0
Kiel Kronshagen
Country [41] 0 0
Germany
State/province [41] 0 0
Muenchen
Country [42] 0 0
Germany
State/province [42] 0 0
Sulzbach-Rosenberg
Country [43] 0 0
Germany
State/province [43] 0 0
Villingen-Schwenningen
Country [44] 0 0
Greece
State/province [44] 0 0
Larissa
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Gyeonggi-do
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Seoul
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Wonju
Country [48] 0 0
Mexico
State/province [48] 0 0
Cuernavaca
Country [49] 0 0
Mexico
State/province [49] 0 0
Hermosillo
Country [50] 0 0
Mexico
State/province [50] 0 0
Jalisco
Country [51] 0 0
Mexico
State/province [51] 0 0
Mexico City
Country [52] 0 0
Mexico
State/province [52] 0 0
Monterrey
Country [53] 0 0
Mexico
State/province [53] 0 0
Pachuca
Country [54] 0 0
Norway
State/province [54] 0 0
Elverum
Country [55] 0 0
Norway
State/province [55] 0 0
Oslo
Country [56] 0 0
Peru
State/province [56] 0 0
Lima
Country [57] 0 0
Poland
State/province [57] 0 0
Bialystok
Country [58] 0 0
Poland
State/province [58] 0 0
Gdansk
Country [59] 0 0
Poland
State/province [59] 0 0
Kamieniec Zabkowicki
Country [60] 0 0
Poland
State/province [60] 0 0
Rzeszow
Country [61] 0 0
Poland
State/province [61] 0 0
Skierniewice
Country [62] 0 0
Poland
State/province [62] 0 0
Sobótka
Country [63] 0 0
Poland
State/province [63] 0 0
Wroclaw
Country [64] 0 0
Puerto Rico
State/province [64] 0 0
Caguas
Country [65] 0 0
Puerto Rico
State/province [65] 0 0
Carolina
Country [66] 0 0
Romania
State/province [66] 0 0
Bucuresti
Country [67] 0 0
Romania
State/province [67] 0 0
Buzau
Country [68] 0 0
Romania
State/province [68] 0 0
Cluj-napoca
Country [69] 0 0
Romania
State/province [69] 0 0
Ploiesti
Country [70] 0 0
Slovakia
State/province [70] 0 0
Levice
Country [71] 0 0
Slovakia
State/province [71] 0 0
Presov
Country [72] 0 0
Slovakia
State/province [72] 0 0
Samorin
Country [73] 0 0
Slovakia
State/province [73] 0 0
Trebisov
Country [74] 0 0
Slovakia
State/province [74] 0 0
Trencin
Country [75] 0 0
South Africa
State/province [75] 0 0
Cape Town
Country [76] 0 0
South Africa
State/province [76] 0 0
Pretoria
Country [77] 0 0
Spain
State/province [77] 0 0
Alicante
Country [78] 0 0
Spain
State/province [78] 0 0
Almeria
Country [79] 0 0
Spain
State/province [79] 0 0
Sevilla
Country [80] 0 0
Spain
State/province [80] 0 0
Valencia
Country [81] 0 0
Sweden
State/province [81] 0 0
Ljungby
Country [82] 0 0
Sweden
State/province [82] 0 0
Stockholm
Country [83] 0 0
Sweden
State/province [83] 0 0
Örebro
Country [84] 0 0
Switzerland
State/province [84] 0 0
Basel
Country [85] 0 0
Switzerland
State/province [85] 0 0
Geneve
Country [86] 0 0
Switzerland
State/province [86] 0 0
Zürich
Country [87] 0 0
Taiwan
State/province [87] 0 0
Taichung
Country [88] 0 0
Taiwan
State/province [88] 0 0
Taipei
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taoyuan County
Country [90] 0 0
Thailand
State/province [90] 0 0
Bangkok
Country [91] 0 0
Thailand
State/province [91] 0 0
Songkla
Country [92] 0 0
Turkey
State/province [92] 0 0
Istanbul
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Bexhill on Sea
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Crawley
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Glasgow
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Hinckley
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Reading

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This 4 arm study will assess the efficacy, safety and tolerability of taspoglutide compared
to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled
with metformin. Patients will be randomized to receive taspoglutide (10mg once weekly or 10mg
once weekly for 4 weeks followed by 20mg once weekly), sitagliptin 100mg once daily or
placebo, in a ratio of 2:2:2:1, in addition to their continued prestudy metformin treatment.
After 24 weeks of treatment, patients on active treatment will continue on the same treatment
and patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide
20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly). The anticipated time on
study treatment is 2+ years, and the target sample size is 500+ individuals.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00754988
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00754988